# Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

> **NCT04781322** · PHASE1 · RECRUITING · sponsor: **National Institute on Alcohol Abuse and Alcoholism (NIAAA)** · enrollment: 100 (estimated)

## Conditions studied

- Alcohol Associated Liver Disease
- Heavy Drinking Behavior

## Interventions

- **DRUG:** Alirocumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04781322
- **Lead sponsor:** National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-19
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781322, "Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04781322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*